Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Infosys Limited
  6. News
  7. Summary
    INFY   INE009A01021

INFOSYS LIMITED

(INFY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REUTERS NEXT-Quotes on Omicron variant from Day 1 of the Reuters Next conference

12/01/2021 | 12:48pm EST

Dec 1 - Reuters Next is hosting three days of interviews, panels and presentations with 150+ global leaders discussing the biggest business, social and environmental challenges for the year ahead.

Following are some notable quotes on the Omicron variant https://www.reuters.com/business/healthcare-pharmaceuticals/omicron-variant-could-outcompete-delta-south-african-disease-expert-says-2021-11-30 of the coronavirus from the first day of the Dec. 1-3 conference.

JOHN MOORE, PROFESSOR OF MICROBIOLOGY AND IMMUNOLOGY AT WEILL CORNELL MEDICAL COLLEGE IN NEW YORK

"It is no coincidence to most of us that (the Omicron coronavirus variant) arose in Sub-Saharan Africa, where you have a lot of under-diagnosed HIV infections, or people who are immunocompromised with it.

"That's how the other variants are thought to have arisen - in immunocompromised people."

KATE BINGHAM, FORMER HEAD OF UK'S VACCINE TASKFORCE

"It's not something you can do overnight, but we will get data, I've would have thought within a week as to whether or not the vaccines work or don't.

"Clearly there's a concern because there's a bunch of mutations that are in a different place and look like they could be concerning. But at the moment, I would still assume that these vaccines will have efficacy. The question is do they have the same level of efficacy"

PASCHAL DONOHOE, PRESIDENT OF THE EUROGROUP OF EURO ZONE FINANCE MINISTERS AND IRISH FINANCE MINISTER

"It is very early days in terms of the health impact of this new variant on all of us. I am confident about our ability to sustain a strong recovery into next year."

"I hope we can avoid those broad health measures again. I am equally confident that we will be able to allow consumption and investment to take place alongside them were they to happen."

"There is a radical imperative in how we deal with the impact of a pandemic on an interdependent world, which is that none of us are safe until all of us are safe."

"The scientists in South Africa created a great public good in detecting what was happening in their country and in sharing it in the way they did and it underlines to me how important it is for us to fulfill our obligations to other parts of the world. That's why European Union is the largest exporter of vaccines."

UNAIDS EXECUTIVE DIRECTOR WINNIE BYANYIMA

People with HIV are at higher risk of severe illness if they become infected with coronavirus, so "for developing countries with a high burden of HIV, (access to COVID-19 vaccines) is critical."

"We do expect that in the coming years, we might see more deaths, we might see more new (HIV/AIDS) infections as a result of these disruptions."

Vaccine nationalism has been "among the saddest part of where we are."

NANDAN NILEKANI, INDIAN TECHNOCRAT, FOUNDER AND CHAIRMAN OF SOFTWARE SERVICES EXPORTER INFOSYS

"We don't know what this variant is, we don't know how infectious it is, we don't know how lethal it is. We'll have to wait and see. But I think companies generally are thinking of a world where COVID will be endemic, there will always be some COVID. Zero count COVID is unlikely ... and hopefully once we finish vaccination there'll be less variants but there'll be new variants coming."

"So we have to start gearing up for creating a preventive environment where people can come to work, work safely, constant testing, vaccination, booster shots and - if an incident happens - very quick isolation. So we just have to get around this and get on with it because it appears this is a fact of life."

To watch the ReutersNext conference please register here https://reutersevents.com/events/next/ (Compiled by Kate Holton, Padraic Halpin, Catherine Evans and Sankalp Phartiyal Editing by Matthew Lewis)


ę Reuters 2021
All news about INFOSYS LIMITED
04:22aINFOSYS POSITIONED AS A LEADER IN ID : Worldwide B2B Commerce Services for Industrial Manu..
AQ
04:22aInfosys Recognized as Global Top Employer for the Second Consecutive Year; Ranked #1 in..
AQ
01/21Indian shares suffer worst week since late Nov, Reliance results in focus
RE
01/20Asian ADRs Move Higher in Thursday Trading
MT
01/20Indian shares tumble on declines in tech firms, Bajaj Finserv
RE
01/20INFOSYS POSITIONED AS A LEADER IN ID : Worldwide B2B Commerce Services for Industrial Manu..
PU
01/19Asian ADRs Move Lower in Wednesday Trading
MT
01/19Indian shares drop to over one-week lows on tech slump
RE
01/19Indian Indices Close in Red Midweek; Oil & Natural Gas Jumps 4%
MT
01/18Asian ADRs Fall Sharply Lower in Tuesday Trading
MT
More news
Analyst Recommendations on INFOSYS LIMITED
More recommendations
Financials
Sales 2022 1 214 B 16 262 M 16 262 M
Net income 2022 225 B 3 018 M 3 018 M
Net cash 2022 269 B 3 607 M 3 607 M
P/E ratio 2022 32,4x
Yield 2022 1,93%
Capitalization 7 279 B 97 449 M 97 520 M
EV / Sales 2022 5,78x
EV / Sales 2023 4,90x
Nbr of Employees 292 067
Free-Float -
Chart INFOSYS LIMITED
Duration : Period :
Infosys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INFOSYS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 39
Last Close Price 1 736,80 INR
Average target price 2 192,72 INR
Spread / Average Target 26,3%
EPS Revisions
Managers and Directors
Salil S. Parekh Chief Executive Officer, MD & Executive Director
Mohit Joshi Co-President
Ravi Kumar S. Co-President & Deputy Chief Operating Officer
Nilanjan Roy Chief Financial Officer
Nandan M. Nilekani Non-Executive Chairman
Sector and Competitors
1st jan.Capi. (M$)
INFOSYS LIMITED-5.41%100 701
ACCENTURE PLC-19.04%212 118
TATA CONSULTANCY SERVICES LTD.2.55%190 800
INTERNATIONAL BUSINESS MACHINES CORPORATION-3.22%116 001
AUTOMATIC DATA PROCESSING, INC.-11.94%91 495
SNOWFLAKE INC.-21.02%81 954